The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia
Open accessAbstract
Tripeptidyl aldehyde proteasome inhibitors have been shown to effectively increase viral capsid ubiquitination and transduction of recombinant adeno-associated virus type 2 (rAAV-2) and rAAV-5 serotypes. In the present study we have characterized a second class of proteasome-modulating agents (anthracycline derivatives) for their ability to induce rAAV transduction. The anthracycline derivatives doxorubicin and aclarubicin were chosen for analysis because they have been shown to interact with the proteasome through a mechanism distinct from that of tripeptidyl aldehydes. Our studies demonstrated that doxorubicin and aclarubicin also significantly augmented rAAV transduction in airway cell lines, polarized human airway epithelia, and mouse lungs. Both tripeptidyl aldehyde and anthracycline proteasome-modulating agents similarly augmented nuclear accumulation of rAAV in A549 and IB3 airway cell lines. However, these two cell types demonstrated cell specificity in the ability of N -acetyl- l -leucyl- l -leucyl- l -norleucine (LLnL) or doxorubicin to augment rAAV transduction. Interestingly, the combined administration of LLnL and doxorubicin resulted in substantially increased transduction (>2,000-fold) following apical infection of human polarized epithelia with either rAAV-2 or rAAV-5. In summary, the cell type specificity of LLnL and doxorubicin to induce rAAV transduction, together with the ability of these compounds to synergistically enhance rAAV transduction in polarized airway epithelial induction, suggests that these two classes of compounds likely modulate different proteasome functions that affect rAAV transduction. Findings from this study provide new insights into how modulation of proteasome function can be effectively used to augment rAAV transduction in airway epithelia for gene therapy of cystic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Use of proteasome inhibitors such as MG-132 and LLnL have been shown to increase transduction, providing evidence that after endosome escape, AAV must elude proteasomes in the cytoplasm while traversing to the nucleus (Fig. 8IV and V) (11, 51).”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have been carried out by a number of groups (11, 22, 50, 51) illustrating that drugs/chemicals such as bafilomycin A, brefeldin A, and MG-132 augment rAAV transduction by acting on the level of endosome acidification, early-to-late endosome transition, and proteasome activity, respectively.”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Proteasome inhibitors have been described in numerous studies to increase the transduction of rAAV postentry of the cell, suggesting that proteasomes are a barrier for intracellular trafficking (11, 51).”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Proteasome inhibitors have been described in numerous studies to increase the transduction of rAAV postentry of the cell, suggesting that proteasomes are a barrier for intracellular trafficking (11, 51).”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“Studies evaluating rAAV trafficking with the fluorescent and radiolabeled virus have demonstrated that once endocytosed, the virus moves relatively slowly to the nucleus and accumulates in a perinuclear compartment (4, 14, 19, 20, 37).”
BackgroundEndosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391
Self-citationYan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Self-citationHansen, J., Qing, K., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4080-4090.2001 · Cited by 129 · cited 1×
“Studies evaluating rAAV trafficking with the fluorescent and radiolabeled virus have demonstrated that once endocytosed, the virus moves relatively slowly to the nucleus and accumulates in a perinuclear compartment (4, 14, 19, 20, 37).”
Background
Research works printed but not linked: 34
- 10.1089/104303401753153956 · DOI
- 10.1172/JCI0215780 · DOI
- 10.1128/JVI.73.7.6085-6088.1999 · DOI
- Berns K. I. and C. Giraud. 1996. Adeno-associated virus (AAV) vectors in gene therapy. Springer Berlin Germany. · DOI
- 10.1023/A:1008323200102 · DOI
- Carter B. J. H. B. Burnstein and R. W. Peluso. AAV vectors for gene therapy in press. Marcel Dekker Inc. New York N.Y.
- Casper, E. S., R. J. Gralla, and C. W. Young. 1981. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule. Cancer Res.41:2417-2420.
- 10.1073/pnas.97.7.3428 · DOI · Paper page
- 10.1128/JVI.77.13.7361-7366.2003 · DOI
- Dong, J., M. Naito, T. Tatsuta, H. Seimiya, O. Johdo, and T. Tsuruo. 1995. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol. Res.7:245-252.
- 10.1089/hum.1998.9.18-2761 · DOI
- Duan, D., Y. Zhang, and J. F. Engelhardt. 1998. Gene delivery to the airway, p. 13.9.1-13.9.34. In N. C. Dracopoli, J. L. Haines, B. R. Korf, D. T. Moir, C. C. Morton, C. E. Seidman, J. G. Seidman, and D. R. Smith (ed.), Current protocols in human genetics, John Wiley & Sons, Inc., New York, N.Y.
- 10.1074/jbc.271.28.16455 · DOI
- 10.2165/00003088-200342050-00002 · DOI
- 10.1073/pnas.182412299 · DOI · Paper page
- 10.1128/JVI.74.2.992-996.2000 · DOI
- 10.1089/104303402320139014 · DOI
- 10.1016/0163-7258(90)90088-J · DOI
- 10.1074/jbc.274.6.3363 · DOI
- Kiyomiya, K., M. Kurebe, H. Nakagawa, and S. Matsuo. 2002. The role of the proteasome in apoptosis induced by anthracycline anticancer agents. Int. J. Oncol.20:1205-1209.
- 10.1016/S0024-3205(98)00151-9 · DOI
- 10.1016/S0962-8924(98)01346-4 · DOI · Paper page
- 10.1074/jbc.272.47.29899 · DOI
- Muller, I., D. Niethammer, and G. Bruchelt. 1998. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int. J. Mol. Med.1:491-494.
- 10.1128/JVI.76.24.12634-12645.2002 · DOI
- 10.1056/NEJM199809243391307 · DOI
- 10.1053/ctrv.2002.0262 · DOI
- 10.1021/bi00154a014 · DOI
- 10.1097/00005537-199902000-00017 · DOI
- 10.1089/hum.1998.9.6-889 · DOI
- 10.1089/104303402760128577 · DOI
- 10.1128/JVI.76.22.11505-11517.2002 · DOI
- 10.1016/S0076-6879(02)46065-X · DOI
- 10.1128/JVI.74.8.3852-3858.2000 · DOI
Cited by
Sorted by citations
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
“In addition, it is also possible that the proteasome effect may be cell type-specific (31, 39, 40).”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
“Studies have been carried out by a number of groups (11, 22, 50, 51) illustrating that drugs/chemicals such as bafilomycin A, brefeldin A, and MG-132 augment rAAV transduction by acting on the level of endosome acidification, early-to-late endosome transition, and proteasome activity, respectively.”
BackgroundSonntag, F., Bleker, S., Leuchs, B., Fischer, R., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.01056-06 · Cited by 297
“Proteasome inhibitors significantly increase gene transduction with AAV2 (12, 14, 16, 23, 34, 75, 76); however, the mechanism of inhibitor action remains unclear,”
BackgroundIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Self-citation
Metadata
- Authors
- Yan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., & Engelhardt, J. F.
- Affiliations
- University of Iowa (US)
- Department of Anatomy and Cell Biology
- Targeted Genetics Corporation, Seattle, Washington 98101
- Corresponding author
- Engelhardt, John F.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2004-03-15
- Volume
- 78
- Issue
- 6
- Pages
- 2863-2874
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC353734
- OpenAlex
- W1982346550
- Cited by
- 138
- References
- 0
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL058340, R01 HL58340)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54759, P30DK054759)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- proteasome inhibitors, adeno-associated virus type 2, doxorubicin, aclarubicin, Lawrence Livermore National Laboratory
- MeSH terms
- Dependovirus, Animals, Cell Line, Cysteine Endopeptidases, Cystic Fibrosis, Doxorubicin, Epithelial Cells, Humans, Leupeptins, Lung, Mice, Inbred C57BL, Multienzyme Complexes, Parvoviridae Infections, Recombination, Genetic, Transduction, Genetic, Aclarubicin, Genetic Therapy, Cysteine Proteinase Inhibitors, Cell Polarity, Proteasome Endopeptidase Complex, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review